Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Can-Fite BioPharma provided an update on the regulatory status of its two Phase III candidates, Namodenoson and Piclidenoson. Namodenoson holds FDA Fast Track and Orphan Drug designations for its pivotal HCC study, while Piclidenoson is advancing in Phase III for psoriasis.
Key figures
- Drug Name
- Namodenoson, Piclidenoson
- Phase Of Trial
- Phase III
- Patients treated
- over 1,600
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.